Loading...
Loading...
TAK| Name | Value |
|---|---|
| Revenues | 1,176.0B |
| Cost of Revenue | 536.7B |
| Gross Profit | 639.3B |
| Operating Expense | 443.8B |
| Operating I/L | 184.2B |
| Other Income/Expense | -64.9B |
| Interest Income | 4.1B |
| Pretax | 119.4B |
| Income Tax Expense | 27.3B |
| Net Income/Loss | 92.0B |
Takeda Pharmaceutical Company Limited is a global pharmaceutical company that focuses on research, development, manufacturing, marketing, and out-licensing of pharmaceutical products. The company's product portfolio includes pharmaceuticals in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. It offers a range of branded pharmaceutical products under various well-known brands such as Entyvio, Gattex/Revestive, Takecab, and others. Takeda also engages in collaborations, in-licensing agreements, and strategic alliances with various biotech and pharmaceutical companies to drive innovation and expand its product offerings.
